Hyperprolactinemia in the postmenopause: versions and contraversions

Abstract

The prevalence of hyperprolactinemia in postmenopausal women is unknown and has been estimated as infrequent by many studies. Prolactinomas found after menopause are usually macroadenomas and remain unrecognized for a long time due to atypical clinical signs or their absence. The growth potential of prolactinomas persists after menopause, most of them are invasive and accompanied by high prolactin levels. Treatment with dopamine agonists is usually long-term, the goals of which are to reduce tumor size, normalize prolactin levels and the negative effects of hyperprolactinemia. Treatment with cabergoline makes it possible to achieve remission of the disease in the first years after discontinuation, however, the proportion of relapses in postmenopausal women increases 5 years after discontinuation of the drug. Remission of prolactinomas is not evident in postmenopausal women. The modern management of patients with prolactinoma and/or hyperprolactinemia does not have clear positions in the postmenopausal period. Controversial issues remain: an ambiguous relationship between prolactin levels and breast cancer, there are no convincing conclusions on the improvement of bone mineral density and/or a decrease in the risk of fractures with normalization of prolactin levels, there are no data on metabolic parameters after the end of treatment with dopamine agonists, conflicting information about the relationship of prolactin levels and the severity of the manifold manifestations of the climacteric syndrome. The use of estrogen-progestin drugs in women with hyperprolactinemia/prolactinomas is also not well understood. Thus, the problem of hyperprolactinemia in the perimenopausal and postmenopausal period is underestimated and requires additional research, as well as the development of diagnostic and therapeutic strategies for potential benefits in terms of weight loss, improving insulin sensitivity, reducing the risk of fractures, maintaining sexuality and psycho-emotional well-being.

Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines

“…Респираторные вирусы активируют воспаление, в том числе Т2, характерное для большинства пациентов с БА. У некоторых пациентов дебют астмы возникает непосредственно в период ОРИ или ассоциирован с перенесенными ранее респираторными инфекциями, вирусными, а также Chlamydophila или Mycoplasma, особенно при атопии в анамнезе 164,165 [1776][1777][1778]. У больного БА с вирусной инфекцией отмечается высокий риск развития вторичной бактериальной инфекции (S. pneumoniae, S. aureus, H. influenzae).…”

Prolactinoma in postmenopausal women: a systematic review

“…3 These tumors can be treated with medication. Recent studies have focused on the therapeutic management of prolactinoma in postmenopausal women [4][5][6] or surgery. 2 Dopaminergic agonists (DAs) are currently the first-line drugs for the treatment of prolactinomas.…”